11 completed, 5 recruiting, 1 enrolling by invitation, 1 not yet recruiting. 6 Phase 2, 6 Phase 3, 4 Phase 1, 4 Phase 4, 1 Not applicable.
Follow gadopiclenol: new trials by email Literature Review of gadopiclenol trials Research Report on gadopiclenol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Screening for Brain Metastases gadopiclenol (contrast agent), standard contrast agent - Lung Cancer Stage IV, Melanoma Stage IV | Phase 2 | Not yet recruiting | University of Zurich | 180 | 2026-09-01 | 2026-03-25 |
| Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease gadopiclenol, Gadoterate meglumine (Dotarem) - Steno-occlusive Disease | Phase 3 | Recruiting | Guerbet | 315 | 2026-07-28 | 2026-10-07 |
| Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease MRI Scan, VUEWAY, Gadavist - Leptomeningeal Disease | Not applicable | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-06-10 | 2026-06-18 |
| Randomized Comparison of Contrast Agents Gadopiclenol and Gadobutrol in the Workup of Incidental Renal and Adrenal Findings Gadobutrol (Gadovist/Gadavist), Gadopiclenol - Suspect Renal and Adrenal Imaging Findings | Phase 4 | Terminated | Insel Gruppe AG, University Hospital Bern | 17 | 2025-08-18 | 2026-10-16 |
| High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment Elucirem (Gadopiclenol) - Myocardial Fibrosis | Phase 4 | Recruiting | Johns Hopkins University | 25 | 2025-08-01 | 2026-04-13 |
| Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging) Gadopiclenol, Gadobutrol (Gadavist, BAY86-4875) - Contrast Enhanced Images vs. Non-contrast Images, Gadopiclinol Enhanced Images vs. Gadobutrol Enhanced Images | Phase 4 | Recruiting | UConn Health | 10 | 2025-03-25 | 2026-04-28 |
| MRI Gadopiclenol Enhanced Imaging of CNS Tumors CE MRI on 0.064T Scanner, Gadopiclenol - Image | Withdrawn | Medical University of South Carolina | 2024-12-30 | 2025-02-04 | ||
| Study of 18F-FFNP Breast PET/MRI 18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole - Breast Cancer | Phase 2 | Recruiting | University of Wisconsin, Madison | 53 | 2024-09-25 | 2026-08-31 |
| Gadopiclenol vs Gadoxetate MRI for Liver Lesions Radiology, Gadopiclenol - Liver Lesion | Enrolling by invitation | Icahn School of Medicine at Mount Sinai | 23 | 2024-07-01 | 2026-04-22 | |
| Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics Gadopiclenol, Gadobenate dimeglumine - Congenital Heart Disease | Phase 3 | Unknown | University of California, San Diego | 160 | 2024-05-01 | 2024-05-09 |
| Gadopiclenol in Contrast Enhanced MRI of the Prostate Gadopiclenol - Prostate Cancer | Phase 4 | Suspended | Columbia University | 150 | 2024-02-14 | 2026-07-20 |
| Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas Elucirem, Dotarem - Brain Tumor, Primary, Brain Tumor, Recurrent | Phase 3 | Completed | Guerbet | 138 | 2023-09-07 | 2026-01-29 |
| Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children Gadopiclenol, Comparator (gadobutrol) - Lesion in Body Region, CNS Lesion | Phase 3 | Completed | Guerbet | 240 | 2023-07-21 | 2026-06-25 |
| Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age Gadopiclenol - Central Nervous System Diseases, Pediatric Disorder | Phase 2 | Completed | Guerbet | 36 | 2022-09-21 | 2025-10-28 |
| Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers gadopiclenol, Placebo - Pharmacokinetics | Phase 1 | Completed | Guerbet | 27 | 2021-05-10 | 2021-10-07 |
| Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution - Lesion in Body Region | Phase 3 | Completed | Guerbet | 324 | 2019-08-27 | 2025-10-27 |
| Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial - CNS Lesion, Blood Brain Barrier Defect | Phase 3 | Completed | Guerbet | 260 | 2019-06-03 | 2025-09-22 |
| Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI P03277 - Central Nervous System Indication, Pediatric Patients | Phase 2 | Completed | Guerbet | 80 | 2018-11-06 | 2022-06-01 |
| Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Function P03277 - Renal Insufficiency, Healthy Volunteers | Phase 1 | Completed | Guerbet | 40 | 2017-10-13 | 2019-10-22 |
| Cardiac Safety Evaluation of P03277 P03277 0.1 mmol/kg, Moxifloxacin 400mg, NaCl 0.9% - Healthy Volunteers | Phase 1 | Completed | Guerbet | 48 | 2017-08-21 | 2022-07-18 |
Showing 20 of 22. Sign in to see all of them.
Brain Neoplasms (1) · Breast Neoplasms (1) · Central Nervous System Diseases (1) · Heart Defects, Congenital (1) · Lung Neoplasms (1) · Melanoma (1) · Meningeal Neoplasms (1) · Prostatic Neoplasms (1) · Renal Insufficiency (1)
Guerbet (12) · Columbia University (1) · Icahn School of Medicine at Mount Sinai (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · M.D. Anderson Cancer Center (1) · Medical University of South Carolina (1) · UConn Health (1) · University of California, San Diego (1) · University of Wisconsin, Madison (1) · University of Zurich (1)
United States (12) · Hungary (7) · Poland (7) · Italy (5) · Belgium (4) · South Korea (4) · France (3) · Germany (3) · Mexico (3) · Spain (3) · Bulgaria (2) · Czechia (2) · Japan (2) · Switzerland (2) · Ukraine (2)
Albert Hsiao, MD/PhD (1) · Amy M Fowler, MD, PHD (1) · Andreas Christe, Prof. Dr. med. (1) · Donna R Roberts, MD (1) · Frantz Hebert (1) · Frederic Vanhoutte, MD (1) · Jing Hao (1) · Joao Lima, Professor (1) · Lorie Loevner, MD (1) · Nicolas Bloch, MD (1) · Penescu Mircea, MD (1) · Rami Eldaya, MD (1) · Sara Lewis, MD (1)
PMID 30870257, PMID 31917762, PMID 34197356, PMID 35318970, PMID 36729404, PMID 37462494
2017 (1), 2018 (1), R01CA272571 (1)